Italy’s antitrust authority has launched an investigation against eight pharma companies, including Novartis and Roche, over suspicion they may have colluded to delay the
The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be ful
Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis' Lucentis (ranibizumab) for leading causes of blindness, raising the prospect o
Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year